Assertio Holdings, Inc. withdrew earnings guidance for the year 2023. The company is withdrawing its 2023 financial outlook to assess the recent news of a generic indomethacin suppository approved by the United States Food and Drug Administration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9901 USD | +5.36% | -0.99% | -7.47% |
May. 30 | Declaration of Voting Results by Assertio Holdings | CI |
May. 30 | Declaration of Voting Results by Assertio Holdings | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.47% | 94.63M | |
+40.73% | 739B | |
+31.08% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.98% | 240B | |
+9.46% | 210B | |
-5.19% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- ASRT Stock
- News Assertio Holdings, Inc.
- Assertio Holdings, Inc. Withdraws Earnings Guidance for the Year 2023